Quick summary: core takeaways

Electronic nicotine delivery systems (ENDS), commonly described as a papieros elektroniczny, were introduced as an alternative to combustible tobacco and as a potential cessation device. However, multiple studies and public health reviews have documented a range of harmful effects of electronic cigarettes that affect the respiratory system, vascular function, and long-term cardiovascular risk. Key points: e-liquids contain nicotine plus other chemicals that create aerosols; aerosols deliver ultrafine particles and volatile compounds deep into the lungs; acute effects include airway irritation, endothelial dysfunction, and increased heart rate; chronic exposure may increase risk for chronic respiratory symptoms, reduced lung function, and atherosclerotic progression. Risk varies by device type, liquid composition, user behavior, and pre-existing health status.

What is inside a typical device?

The typical papieros elektroniczny uses a battery to heat a coil that vaporizes a liquid mixture (commonly called e-liquid or vape juice). Standard components that matter for health impacts include: nicotine (in variable concentrations), solvents such as propylene glycol (PG) and vegetable glycerin (VG), flavoring chemicals (diacetyl and many others), metal particles from coils (nickel, chromium, lead traces), and thermal decomposition products such as formaldehyde, acetaldehyde, and acrolein. These constituents are not inert when inhaled; they interact with airway tissues and the circulatory system producing biological responses that underlie the harmful effects of electronic cigarettes.

Mechanisms of respiratory harm

Aerosolized particles from an e-cigarette penetrate deeply into the alveolar spaces. Key mechanisms include oxidative stress, inflammatory signaling, disruption of epithelial barrier function, and impairment of mucociliary clearance. Combined, these effects reduce the lung’s defenses against pathogens and environmental insults. Research demonstrates that use of a papieros elektroniczny can acutely increase airway resistance, cause bronchial hyperresponsiveness in susceptible individuals, and trigger inflammation markers such as interleukins and tumor necrosis factor—pathways linked to asthma exacerbation and chronic bronchitis-like symptoms.

Cardiovascular pathways affected

The harmful effects of electronic cigarettes on heart and vessels are mediated by nicotine-driven sympathetic activation, endothelial dysfunction caused by oxidative stress, and pro-thrombotic signaling. Nicotine raises heart rate and blood pressure transiently; fine particles and chemical irritants impair nitric oxide availability which is essential for vasodilation. Over time, these changes can accelerate atherosclerosis, increase arterial stiffness, and raise risks for myocardial ischemia and stroke. Studies using vascular ultrasound and biomarkers report acute reductions in flow-mediated dilation after vaping episodes—an indicator of reduced endothelial health.

Comparisons with combustible cigarettes: risk continuum not absence of risk

Some authorities describe e-cigarette use as a potentially reduced-exposure alternative compared to traditional cigarettes, particularly for adult smokers switching completely. However, “reduced exposure” is not the same as “safe.” The literature indicates that while some toxicants are lower than in tobacco smoke, many novel compounds are present and long-term epidemiologic data remain limited. The harmful effects of electronic cigarettes must be considered in the context of dose, dual use (vaping plus smoking), and the young population uptake where any added risk is unacceptable.

Vulnerable populations and heightened risks

Certain groups are at higher risk from inhaling e-cigarette aerosols: adolescents and young adults (due to developing lungs and brain vulnerability to nicotine), pregnant people (nicotine harms fetal development), individuals with chronic respiratory disease (COPD, asthma), and people with established cardiovascular disease. Nicotine use during adolescence also increases the likelihood of transitioning to combustible tobacco products, amplifying lifetime harm beyond the direct harmful effects of electronic cigarettes.

Real-world evidence: clinical and epidemiological findings

Several population-level and clinical studies have linked e-cigarette use with increased respiratory symptoms (cough, wheeze, shortness of breath), greater odds of chronic bronchitis symptoms, and new-onset asthma symptoms. On the cardiovascular side, cross-sectional analyses show associations between vaping and self-reported myocardial infarction and stroke after adjusting for some confounders. While causality is still being established for long-term outcomes, the convergence of biological plausibility, short-term physiologic changes, and observational associations suggest non-trivial risk.

Acute harms: EVALI and other severe presentations

A subset of acute lung injuries, including the 2019 outbreak labeled EVALI (e-cigarette or vaping product use-associated lung injury), demonstrated that inhalation of certain adulterants (e.g., vitamin E acetate in THC-containing products) can cause life-threatening respiratory failure. EVALI underlined that additives and contaminants in e-liquids can produce severe alveolar damage. Although widely publicized examples often involved illicit products, they emphasize that a papieros elektroniczny aerosol is capable of conveying highly toxic substances to the lower respiratory tract.

Flavorings and chemical additives: underestimated threats

Many flavoring agents used to improve palatability are generally recognized as safe (GRAS) when ingested, but inhalation exposure can produce different toxicological profiles. Compounds such as diacetyl have been linked to bronchiolitis obliterans (“popcorn lung”) in occupational exposures, and other flavoring chemicals produce oxidative stress and mitochondrial dysfunction in airway cells. Marketing of flavored products has also been a major driver of youth use, increasing the public health impact of the harmful effects of electronic cigarettes.

Quantifying exposure: dose, frequency, and device factors

Risk is not binary. Higher concentrations of nicotine, more frequent use, higher power devices that create hotter aerosols, and liquid formulations with certain solvents or additives all increase potential harm. Sub-ohm vaping, nicotine salts (allowing higher nicotine delivery with less irritation), and social habits like taking long puffs or “chain vaping” magnify exposure to nicotine and thermal decomposition by-products. Thus, user behavior and product design are critical in determining the net effect on health.

Harm reduction, smoking cessation, and clinical guidance

Medical organizations diverge in recommendations. Some recognize the potential for adult smokers who fully switch from cigarettes to vaping to reduce some exposures, while also warning about persistent risks and advocating evidence-based cessation tools (nicotine replacement therapy, counseling, approved medications) as first-line. Clinicians should assess: is the patient a current smoker unwilling or unable to quit with first-line therapies? If so, a managed transition may be considered while emphasizing complete switching and long-term cessation as the goal. Importantly, promoting e-cigarette use among non-smokers, especially youth, is strongly contraindicated.

Regulatory and public health implications

Policy responses vary across countries; some emphasize strict product standards, flavor restrictions, nicotine limits, age controls, and marketing curbs to reduce youth uptake while preserving adult access for cessation. Regulators increasingly require ingredient disclosure, emissions testing, and premarket safety evaluations to mitigate known pathways of harm. The ongoing debate balances potential harm reduction for adult smokers against the clear harms of growing youth initiation and nicotine dependence.

Practical advice for users and caregivers

• Do not start use if you are a non-smoker—there is no safe level of inhaled nicotine for youth or pregnant people.
• If you smoke combustible cigarettes, speak to healthcare professionals about established cessation methods first; if switching to a papieros elektroniczny is considered, aim for complete transition and eventual cessation of all nicotine products.
• Avoid modifying devices or using illicit cartridges or homemade liquids—these greatly increase risk.
• Watch for respiratory symptoms such as persistent cough, wheeze, increased sputum, or shortness of breath and seek medical care promptly.

Design and research gaps: what we still need to know

Longitudinal studies tracking exclusive e-cigarette users over decades are scarce; therefore, the long-term cardiovascular and pulmonary disease incidence attributable solely to vaping remains uncertain. Important research priorities include the relative risk compared with smoking across different disease endpoints, the impact of flavoring chemicals, the role of device temperature and aerosol chemistry, and population-level modeling of youth initiation versus adult cessation benefits. These gaps mean caution is prudent in public messaging and regulation.

Communication and public messaging strategies

Clear, balanced messages are crucial: convey that a papieros elektroniczny may reduce exposure to certain tobacco smoke constituents for smokers who completely switch, but emphasize the documented harmful effects of electronic cigarettes and the absence of safety assurance for long-term inhalation. Messaging should be tailored: for youth it must be discouraging and preventative; for adult smokers it should prioritize evidence-based cessation while offering factual information about relative risks and unknowns.

Clinical red flags and when to escalate care

Urgent evaluation is indicated for high fevers, severe shortness of breath, chest pain, hemoptysis, or syncope after vaping. Consider imaging, oxygenation assessment, bronchoscopy in select cases, and consult pulmonary specialists for suspected severe inhalational injury. For cardiovascular events, follow standard protocols while exploring vaping as a potential precipitant in otherwise unexplained cases.

Concluding perspective

In summary, the devices commonly called papieros elektroniczny deliver complex aerosols that can produce acute and chronic biological effects consistent with lung injury and vascular dysfunction. The accumulating body of evidence on the harmful effects of electronic cigarettes supports cautious regulation, targeted public health interventions to prevent youth use, and careful clinical guidance for adult smokers considering switching. Reducing population-level harms will require coordinated policy, robust research, transparent industry standards, and continued health education.

Additional resources and reading

For clinicians and curious readers, consult national public health agency summaries, peer-reviewed systematic reviews on vaping and cardiopulmonary outcomes, and clinical practice guidance on tobacco cessation. Reliable resources update frequently as new evidence emerges; prioritize sources that disclose study limitations and conflicts of interest.

This article aims to be a balanced, search-optimized, and practical resource for understanding the respiratory and cardiovascular concerns linked to modern vaping products and the broader implications for public health and clinical practice.